ClinicalTrials.Veeva

Menu

Diabetes Mellitus Type II and Tissue Oxygenation

NeuroTherapia, Inc. logo

NeuroTherapia, Inc.

Status

Terminated

Conditions

Diabetes Mellitus, Type II

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to determine whether diabetics have decreased amounts of oxygen in the skin compared to non-diabetic individuals, and if the amount of oxygen in the skin changes when given more oxygen to breathe around the time of surgery. To do this, the investigators will be measuring the amount of oxygen in the skin of diabetic and non-diabetic individuals who will be undergoing abdominal surgery lasting 2-4 hours. These measurements will be taken at three different times.

Full description

The goal is to test the hypothesis that: 1) perioperative subcutaneous oxygenation (PsqO2) is lower in diabetic than non-diabetic patients; and, 2) supplemental oxygen provides less benefit in diabetic than non-diabetic patients.

We propose a prospective case-control study which will include 30 Type II diabetics matched for age, sex, and race to 30 non-diabetic controls. Patients will be preselected from a population undergoing abdominal surgery and given supplemental inspired oxygen of 30 - 80% to PaO2 of approximately 150mmHg and/or 300mmHg at three timepoints in the perioperative period. PsqO2 will be measured with an IV-sized probe inserted through a small incision made in the skin. Data will be recorded and analyzed using unpaired two tailed t-test, Wilcoxon's ranked sum test, or repeated-measures analysis of variance (ANOVA) test as appropriate.

Enrollment

60 patients

Sex

All

Ages

35 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

We will include 30 patients who have more than a five-year history of insulin-dependent type-2 diabetes mellitus and 30 non-diabetic patients meeting the following criteria:

  • 35 - 65 yrs old
  • BMI < 30
  • ASA class I - III
  • Abdominal surgery scheduled to last between 2- 4 hours

For Non-diabetic group:

previous BMP within the last year demonstrating glucose < 126mg/dL

For Diabetic group:

  • DMII defined as fasting plasma glucose of > 126 mg/dL at time of diagnosis, now requiring insulin
  • At least one diabetes associated vasculopathy: coronary artery disease, diabetic nephropathy, hypertension, diabetic retinopathy, diffuse neuropathy, peripheral vascular disease, or a history of stroke

Exclusion criteria

  • Pregnant
  • Immunocompromised: HIV/AIDS, on immunosuppressant therapy for any reason, or post-organ transplantation.
  • Infection or fever, or on glucocorticoids
  • Malignancy currently requiring radiation or chemotherapy
  • Liver or renal failure
  • Pancreatic insufficiency, dysautonomia, thyroid disease, Raynaud's syndrome, pathologic Allen-test, or any coagulopathies
  • Respiratory disease affecting ability to reach PaO2 of 300mmHg: COPD, emphysema, cystic fibrosis, asthma, pneumonia, PE
  • Smoker within the past 6 months or current alcohol abuse
  • Allergy to local anesthetic
  • For diabetics: DMI, other specific subtype, and gestational diabetics
  • We will also exclude patients with epidural catheter, to avoid the influence of regional anesthesia on tissue oxygenation [37, 38].

Trial design

60 participants in 2 patient groups

1
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems